PARMAX
Parmax Pharma financials
- Market cap
- ₹12 Cr
Quarterly results
Q1 FY27: revenue up 323.7%, net profit up 389.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 6 | 5 | 2 | 3 −73% | 4 −31% | 3 −31% | 8 +324% |
| EBITDA | 0 | 0 | -1 | -0 | -2 −895% | -0 −282% | -2 −177% | 1 +432% |
| Net profit | -0 | -0 | -1 | -1 | -2 −845% | -1 −87% | -1 +61% | 2 +389% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +274.0% 1Y
1Y: ₹35.76 on 5 Sept 2025 → ₹133.75. High ₹133.75 (7 Sept 2026), low ₹25.22 (27 Mar 2026).
Financials, as filed
Revenue grew 4.6% a year over 2 years, FY24 to FY26. Operating margin widened to -29.6%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹11 Cr | ₹28 Cr | ₹12 Cr |
| Operating profit | ₹-3 Cr | ₹0 Cr | ₹-4 Cr |
| Operating margin | -30.5% | 0.9% | -29.6% |
| Interest | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Depreciation | ₹2 Cr | ₹1 Cr | ₹1 Cr |
| Net profit | ₹-6 Cr | ₹-2 Cr | ₹-4 Cr |
| Net margin | -52.0% | -7.4% | -34.3% |
| Cash from operations | ₹-0 Cr | ₹-1 Cr | ₹-2 Cr |
| Free cash flow | ₹-2 Cr | ₹-2 Cr | ₹-3 Cr |
| ROCE | -58.4% | -12.4% | -83.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr |
| Reserves | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹-4 Cr | ₹-9 Cr | ₹-11 Cr |
| Borrowings | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹12 Cr | ₹12 Cr |
| Other liabilities | ₹11 Cr | ₹7 Cr | ₹6 Cr | ₹9 Cr | ₹11 Cr | ₹23 Cr |
| Total liabilities | ₹23 Cr | ₹18 Cr | ₹18 Cr | ₹15 Cr | ₹18 Cr | ₹28 Cr |
| Fixed assets | ₹11 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹8 Cr | ₹8 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹12 Cr | ₹8 Cr | ₹8 Cr | ₹6 Cr | ₹9 Cr | ₹20 Cr |
| Total assets | ₹23 Cr | ₹18 Cr | ₹18 Cr | ₹15 Cr | ₹18 Cr | ₹28 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Sep 2026
Since Sep 2025, the public trimmed −33.88 pp while promoters added +33.86 pp. The shareholder count shrank 10% to 2,151.
- Promoters
- 64.7%
- Public
- 35.3%
Since Sep 2025
- Public −33.88 pp
- Promoters +33.86 pp
How it drifted, 12 quarters
Over this window promoters went from 30.8% to 64.7% — +33.9 pp.
Ownership split by quarter, oldest first. Dec '23: Promoters 30.8%, Public 69.2%.Mar '24: Promoters 30.8%, Public 69.2%.Jun '24: Promoters 30.8%, Public 69.2%.Sep '24: Promoters 30.8%, Public 69.2%.Dec '24: Promoters 30.8%, Public 69.2%.Mar '25: Promoters 30.8%, Public 69.2%.Jun '25: Promoters 30.8%, Public 69.2%.Sep '25: Promoters 30.8%, Public 69.2%.Dec '25: Promoters 30.8%, Public 69.2%.Mar '26: Promoters 30.8%, Public 69.2%.Jun '26: Promoters 30.8%, Public 69.2%.Sep '26: Promoters 64.7%, Public 35.3%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Dhiren Chandulal Shah newly disclosed 15.58% held
- Hiren Pravin Doshi newly disclosed 5.61% held
- Nirmal Sunilbhai Shah newly disclosed 4.21% held
- Kamlesh Natvarlal Shiyani newly disclosed 4.17% held
- Mili Saumil Shah newly disclosed 4.15% held
- Vijaykumar Natvarlal Shiyani newly disclosed 4.15% held
- Urvi Manish Kothari newly disclosed 4.15% held
- Fredun Nariman Medhora newly disclosed 4.15% held
The same filing shows 1 holder trimming and 3 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2026 filing
Every holder of Parmax Pharma Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Dhiren Chandulal Shah | 15.58% | newly disclosed |
| Abhay Chinubhai Shah | 8.27% | +1.68 pp |
| Umang Alkesh Gosalia | 7.89% | +2.54 pp |
| Gosalia Meena Alkesh | 6.90% | −5.79 pp |
| Hiren Pravin Doshi | 5.61% | newly disclosed |
| Nirmal Sunilbhai Shah | 4.21% | newly disclosed |
| Kamlesh Natvarlal Shiyani | 4.17% | newly disclosed |
| Mili Saumil Shah | 4.15% | newly disclosed |
| Vijaykumar Natvarlal Shiyani | 4.15% | newly disclosed |
| Urvi Manish Kothari | 4.15% | newly disclosed |
| Fredun Nariman Medhora | 4.15% | newly disclosed |
| Dhairya Dhiren Shah | 3.12% | newly disclosed |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Parmax Pharma Limited
Guides on how to read this kind of business and the numbers that matter.